Here's a clinical reality that most telehealth GLP-1 patients don't know: at many platforms, after your initial prescription is written, there is no required follow-up visit. Zero. You receive your medication, inject weekly, and the next time a clinician evaluates you might be never — unless you initiate contact yourself.
This isn't an accident. It's a business model designed for conversion speed, not clinical outcomes. And as state medical boards tighten oversight, it's becoming increasingly difficult to defend.
What the Standard of Care Requires
Medical guidelines are explicit about GLP-1 follow-up. The emerging consensus recommends check-ins at 1, 3, 6, and 12 months at minimum. At each follow-up, clinicians should review:
- Weight loss progress and trajectory
- Side effect management (GI symptoms, injection site reactions)
- Dose titration decisions (when to increase, when to hold)
- Metabolic markers (via lab work at 3-month intervals during the first year)
- Screening for serious complications: pancreatitis symptoms, gallbladder issues, thyroid changes, kidney function
- Behavioral and nutritional support needs
- Medication continuation versus discontinuation planning
State medical boards are increasingly checking whether contraindication screens and informed consent happened at the same visit as the prescription. Follow-up isn't just good practice — it's becoming a regulatory expectation, and boards are conducting retroactive audits of telehealth prescribers.
Why Some Platforms Skip Follow-Up
The economics are straightforward. Follow-up visits cost money — clinician time, scheduling infrastructure, documentation, lab ordering and review. A platform that charges $99/month for compounded semaglutide operates on thin margins. Adding quarterly clinician visits, lab panels, and dose adjustment consultations could double the operational cost per patient.
The result: platforms optimize for the front of the funnel (sign-up, initial evaluation, first prescription) and deprioritize the back end (monitoring, follow-up, dose management, discontinuation planning). The patient fills the gap themselves — Googling side effects, adjusting their own injection timing, and hoping for the best.
This isn't universal. Some platforms build robust follow-up into their programs — Calibrate, for instance, structures quarterly monitoring and coaching into their subscription. But these platforms typically charge more, which means the cheapest options tend to have the least clinical infrastructure.
The Risks of No Follow-Up
GLP-1 medications are not set-and-forget. Without clinical monitoring:
- Dose titration goes unmanaged: The standard protocol involves gradual dose escalation. Without a clinician managing the titration, patients may stay on subtherapeutic doses too long or escalate too quickly, worsening side effects.
- Serious side effects get missed: Pancreatitis, gallbladder disease, and thyroid changes can develop gradually. Without monitoring, early warning signs go undetected until they become emergencies.
- Metabolic changes go untracked: Rapid weight loss affects kidney function, liver enzymes, and nutritional status. Without labs, you're flying blind.
- No off-ramp planning: When you stop a GLP-1 medication, weight regain is well-documented — patients typically regain roughly two-thirds of lost weight within a year. Emerging research suggests cardiovascular "metabolic whiplash" from abrupt discontinuation. Without a provider managing the off-ramp, you're on your own.